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Separation and quantitation of the "middle molecules" in ure-
mia. A modification of a two-stage chromatographic procedure
(molecular sieve followed by ion-exchange) to separate poten-
tially toxic uremic "middle molecules" from body fluids has
been established. The procedure has an analysis time less than
half that previously reported with improved resolution. Elution
volumes have been found to be reproducible to within 2% and
concentrations (as measured by peak height) to within 10%.
Careful attention, however, must be paid to artifacts that may
anse from sample preparation, drug therapy, and dialysis condi-
tions. Up to ten identifiable subpeaks were observed in sera,
urine, and red cell hemolysate samples following ion-exchange
separation of a molecular sieve peak in the middle molecule
range (300 to 2000 daltons). Red cell concentrations of five of
these moieties were significantly higher than those in serum.
Four peaks were not detected at all in red cells, and one peak
was not detected in sera or urine samples. In addition, although
serum concentrations are elevated in uremia, red cell levels in
patients with uremia are comparable with those obtained in nor-
mal subjects. If any of these species are subsequently shown to
be uremic toxins, then their two-compartment distribution within
the body has important ramifications in the choice of an appro-
priate mathematic model to program optimal dialysis therapy.
Separation et quantification des "moyennes molecules" uré-
miques. Une modification de Ia technique de chromatographie
(tamisage moléculaire suivi d'échange ionique) en deux étapes
en vue de sCparer les "moyennes molCcules' toxiques dans
l'urëmie a été réalisée. Le procCdd dure moitié moms longtemps
que celui antCrieurement ddcrit et a une meilleure resolution.
Les volumes d'élution sont reproductibles a 2% et les concentra-
tions (measurées par les hauteurs de pics) a 10%. Une grande vigi-
lance est cependant nécessaire a l'égard les artéfacts qui peu-
vent provenir de Ia preparation de l'échantillon, du traitement
médicamenteux et des conditions de dialyse. Jusqu'à dix pies
identifiables ont dtd observes dans le serum, l'urine et les he-
molysats de globules rouges après separation par echange io-
nique d'un pic de tamisage molCculaire dans Ia zone des
moyennes molecules (300 a 2000 daltons). Les concentrations
dans les erythrocytes de 5 de ces fractions sont significativement
supérieures a celles du serum. Quatre pics n'ont pas du tout été
observes dans le serum ou les unnes. De plus, bien que les con-
centrations seriques soient ClevCes dans l'urémie, les concentra-
tions érythrocytaires sont comparables chez les sujets urC-
miques et les normaux. S'il est ultérieurement avérd que l'une
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de ces espéces est une toxine urémique, Ia distribution bi-com-
partimentale aura des consequences importantes dans le choix
d'un modèle mathématique adéquat permettant de programmer
une dialyse optimale.
Despite the success achieved in treating chronic
renal failure with both hemodialysis and peritoneal
dialysis, there is continuing debate over the bio-
chemical cause of many of the symptoms associated
with uremia. One of the principal theories arising
from this debate is the so-called "middle molecule"
hypothesis, first proposed by Babb et al in 1972 [1],
which suggests that many of the abnormalities of
uremia are caused by the retention of moieties in
the molecular weight range of 300 to 2000 daltons.
This hypothesis, which was based on circumstantial
evidence, remains, however, unproven, as to date
no toxic middle molecule has been identified.
Fürst et at [2] and FUrst, Zimmerman, and
Bergstrom [3] described a two-stage chromato-
graphic procedure for the isolation of substances
whose molecular weights fall in the range of the
"middle molecule." Using a molecular sieve (Seph-
adex G15), followed by ion-exchange (DEAE Seph-
adex A25) chromatography, they demonstrated a
number of abnormalities in the sera of patients with
uremia and suggested that some of these may be re-
lated to specific lesions, such as uremic pericarditis
[3].
We describe our modification of FOrst et al's
method. Our method allows a substantial reduction
in analysis time, together with an improvement in
peak resolution during ion-exchange chromatogra-
phy. We also detail a number of potentially mis-
leading artifacts associated with sample preparation
and chromatogram interpretation. Results, present-
ed from the analysis of both normal and uremic
body fluids, provide further insight into the bio-
chemical abnormalities of uremia.
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Analytic system. The chromatography system is
shown schematically in Fig. 1. Samples were in-
troduced into the system via an injection valve and
pumped directly onto the top of the molecular-sieve
glass column (75 cm x 0.4 cm I.D.) packed with
Sephadex G15 (Pharmacia, Uppsala, Sweden). The
sample was eluted from the column at a flow rate of
10.0 mllhr with 0.01 M Tris buffer (PH, 8.6), and the
eluant was monitored by a fixed wave-length spec-
trophotometer set at 254 nm (model 153, Altex,
Berkeley, California). Any peak eluted from the
molecular-sieve column could be transferred by
means of a four-way valve to the top of the sample
ion-exchange glass column (30 cm X 0.4 cm I.D.)
packed with DEAE Sephadex A25 (Pharmacia,
Uppsala, Sweden). The sample ion-exchange col-
umn was run in parallel with a similar reference col-
umn to eliminate baseline drift, which results from
change in the absorbance of the eluting buffer. Elu-
tion was by a linear gradient of 0 to I M sodium
chloride in 0.01 M Tris buffer (pH, 8.6) at a flow rate
of 12.5 mllhr. The eluant from the ion-exchange col-
umn was monitored by a variable wave-length spec-
trophotometer (model 770, Spectrophysics, Santa
Clara, California), normally set at 215 nm. The out-
put from both spectrophotometers was recorded on
a two-channel strip chart recorder (Rikadenki, To-
kyo, Japan). Because both spectrophotometers
were run in the absorbance mode, quantification of
the peaks could be obtained by measuring peak
height. All results have been expressed in terms of
peak-height units per milliliter (PHU/mI) of sample,
where I PHU is equivalent to 0.01 absorbance units
under the conditions of analysis. All buffers were
prefiltered through a O.2-p. filter (Sartorius,
Gottingen, Germany) and degassed.
Sample preparation. Blood samples were collect-
ed, with or without anticoagulation, centrifuged,
and the serum was stored frozen. All subjects gave
informed consent according to the principles of the
Declaration of Helsinki.
Red cell hemolysates were prepared from blood
collected into heparinized tubes, red cell volume
being obtained from simultaneously determined he-
matocrits. Serum was removed from the sample fol-
lowing centrifugation, and the cells were washed
three times with sterile isotonic saline prior to re-
suspending them to their original volume in distilled
water. After having been frozen and thawed, the he-
molysate was centrifuged. The cell debris was dis-
carded. Hemolysates were stored frozen.
Prior to analysis, both serum and red cell hemoly-
sate samples were thawed and deproteinized by ul-
trafiltration through a 25,000-dalton cut-off mem-
brane (Centriflo CF-25, Amicon, Lexington, Massa-
chusetts).
Urine and spent dialysate samples were collected
into bottles containing 10% thymol in isopropanol
as a preservative. Aliquots were filtered through a
O.22-s filter (Millipore, Bedford, Massachusetts)
before being stored frozen.
Sera, urine, and red blood hemolysate samples
from three normal male volunteers and from pa-
tients with renal failure of varying etiology on main-
tenance hemodialysis were analyzed, together with
spent dialysate samples from the treatment of the
dialysis group. Pooled serum, from both dialyzed
and nondialyzed patients with uremia, was used in
assessing the reproducibility of the assay. The
serum sample size was 500 l, whereas the urine
and hemolysate sample sizes were 100 pi.
Results
Molecular-sieve chro,natography. Initial separa-
tion by molecular-sieve chromatography resolved
the various biologic fluids into 7 to 10 peaks (Fig. 2).
The separation is almost identical to that obtained
by FOrst et al [2], except for a reduction in peak 9
due to the use of a lower molecular-weight cut-off
ultrafiltration cone (25,000, compared to 50,000 dal-
tons). To avoid confusion, we have retained their
Fig. 1. Schemata of chromatographic system.
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Fig. 2. Typical nolecular sieve (Sephadex G15) separations of
serum and urine from normal subjects and patients with uremia.
peak numbering system for both molecular-sieve
and ion-exchange separations. There are consid-
erable differences between the elution patterns of
normal and uremic sera, with more peaks being
eluted in the latter (Fig. 2).
Calibration of the molecular-sieve column. It was
impossible to obtain a size calibration of the molec-
ular-sieve column when we used 0.01 M Tris buffer
to elute the following substances: glucagon (mol wt,
3485 daltons; E. Lilly and Co., Indianapolis, In-
diana), vasopressin (mol wt, 1056 daltons; Sandoz
Ltd., Basle, Switzerland), angiotensin (mol wt, 923
daltons; Ciba, Basle, Switzerland), hexaglycine
(mol wt, 361 daltons; Cyclo Chemical Corp., Los
Angeles, California), creatinine (mol wt, 113 dal-
tons; B.D.H. Ltd., Poole, England), and uric acid
(mol wt, 168 daltons; B.D.H. Ltd., Poole, England).
This was probably due to interactions between the
marker molecules and residual ion-exchange sites
G VAG6 C U
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Fig. 3. Molecular sieve separation of uremic seru,n using 0.1 M
Tris buffer (pH, 8.6) showing elution position of mnolecular
weight ,narkers. G is glucagon (mol wt, 3485 daltons); V is vaso-
pressin (mol wt, 1056 daltons); A is angiotensin (mol wt 923 dal-
tons); G. is hexaglycine (mol wt, 361 daltons); C is creatinine,
(mol wt, 113 daltons); and U is uric acid (mol wt, 168 daltons).
on the Sephadex G15. A satisfactory calibration
was obtained, however, with 0.1 M Tris buffer. It
was found also that when 0.1 M Tris was used the
elution pattern of uremic sera was identical to the
pattern obtained with 0.01 M Tris and, thus, allowed
a size calibration of the molecular-sieve column as
shown in Fig. 3. The anomolous behavior of uric
acid appeared to be due to absorption to the Seph-
adex G15. Although a buffer strength of 0.1 M elimi-
nated the ion-exchange sites on the Sephadex G15
gel, a buffer strength of 0.01 M was retained for rou-
tine operation because this gave enhanced resolu-
tion in subsequent ion-exchange separations.
Ion-exchange chromatography. It has been sug-
gested [3] that peak 7 is related to various uremic
lesions, and, because its apparent molecular weight
of about 1000 daltons (see Fig 2) falls within the mo-
lecular weight range of middle molecules [1], we
chose to examine this peak further by ion-exchange
chromatography.
The chromatograms (Fig. 4) showed that peak 7
could be separated by ion-exchange chromatogra-
phy into a further nine subpeaks. Ion-exchange sep-
aration of peaks 6 to 9 showed that subpeaks were
obtained only from peaks 6 and 7. Because peak 7
was, in general, poorly separated from peak 8 but
comparatively well separated from peak 6, the peak
7 fraction transferred to the ion-exchange column
(from 3.8 to 6.2 ml) routinely contained part of peak
8 to enable accurate quantitation of the peak 7 sub-
peaks. But because of occasional overlap between
peaks 7 and 6 of the molecular sieve separation, a
number of subpeaks arising from peak 6 appeared in
Normal serum
• I I I
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the ion-exchange chromatogram. These all eluted
between the initiation of the gradient and peak 7g
and did not present any problem in quantifying the
subpeaks of peak 7.
Reproducibility. The reproducibility of the proce-
dure was established by repeated analyses of
pooled uremic serum (N = 6) and normal urine sam-
ples (N = 5). Table I gives the results for the ion-
exchange separation of peak 7. Peak elution vol-
umes displayed a high degree of reproducibility (co-
efficients of variations s 2.1%). The slight dif-
ference in elution volumes between the two samples
was due to the use of different batches of ion-ex-
change gel. Apart from peak if in the normal urine,
coefficients of variation for peak heights were
< 9%. The higher value for peak 7f in the normal
urine sample was due to the peak appearing as a
poorly resolved shoulder on peak 7g.
The relationship between peak height and con-
centration was examined by analyzing serial dilu-
tions of a sample of normal urine over a 16:1 range.
Over this range, peak height was found to be a lin-
ear function of concentration for all subpeaks, with
regression coefficients of  0.99.
Artfactual peaks. Chromatogramsof spent dialy-
sate showed a shoulder on peak 7 and an unexpect-
edly high peak height for subpeak 7f. Analysis of
unused dialysate showed a single peak in the region
of peak 7 that eluted in the position of 7f on the ion-
exchange column. Acetate is the only normal con-
stituent of dialysate that will absorb light at 215 and
254 nm, and analysis of a solution of sodium acetate
at the normal dialysate concentration (40 mmoles/
liter) confirmed that the unknown peak was acetate.
This peak was also seen in the chromatograms of
postdialyzer serum samples taken from patients
during hemodialysis. The level of acetate in venous
serum in normal subjects is 0.025 mmoles/liter
and in dialyzed patients with uremia 0.027 mmoles/
liter [4]. Analysis of a solution of 0.03 mmoles/liter
sodium acetate failed to produce a peak in either the
molecular sieve or ion-exchange chromatograms,
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Fig. 4. Typical ion-exchange (DEAE Sephadex A25) separations
of peak 7 from molecular sieve separations of serum and urine
samples fro,n normal subjects and patients with uremia.
Table 1. Reproducibility of multiple analyses of pooled samples of sera from patients with uremia and of urine from normal subjects
Peak
Elution volum&', ml Concentration,PHU/ml
Pooled uremic sera(N = 6)
Normal urine(N = 5)
Pooled uremic sera(N = 6)
Normal urine
(N = 5)
7a0
7a
7b
7c1
7c2
7d
7e
7f
7g
25.8 (2.1)a
23.4 (1.7)
20.7 (1.6)
18.1 (1.4)
17.1 (1.5)
15.4(1.6)
ND
11.5(1.6)
10.4 (1.2)
22.8 (1.5)
20.5 (1.6)
19.2 (1.5)
17.4 (1.6)
16.7 (1.6)
15.2(1.5)
ND
11.2(1.3)
10.1 (1.4)
4 (9.8)
7 (8.7)
34 (5,9)
30 (4.7)
28 (4.5)
16.5(8.5)
ND
149 (6.3)
98 (3.9)
8.5 (4.9)
23 (3.3)
40 (7.2)
38 (7.2)
35 (8.8)
1 (8.4)
ND
29 (12.4)
71 (8.5)
a PHU is peak-height units. N denotes number of analyses. Values in parentheses denote the coefficient of variation, in percent. ND
denotes nondetectable.
This should strictly be the ionic strength of the gradient at which the peak elutes.
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indicating that normal acetate levels are not detect-
able by our analytic method, and, by inference, that
subpeak 7f is not acetate. This artifact could be
eliminated by increasing the buffer strength to 0.1
M. This, however, was undesirable, as resolution in
the subsequent ion-exchange separation would
have been decreased.
Initially, 24-hour urine specimens were collected
in bottles with 5 ml of concentrated hydrochloric
acid as preservative. Analysis of urine collected this
way showed unexpectedly small peaks in the region
of peaks 7 to 9 and in the ion-exchange chromato-
gram of peak 7. Subsequently, a fresh sample of
urine was collected and divided into three parts.
One aliquot was set aside as a control, concentrated
hydrochloric acid (one drop to 10 ml urine) was add-
ed to the second, and an alternative preservative
(10% thymol in isopropanol, 2 drops to 10 ml of
urine) was added to the third aliquot. The three
samples were allowed to stand at room temperature
for 2 hours, stored frozen, and analyzed 7 days lat-
er. In the acid sample, subpeaks 9 to 5 on the molec-
ular-sieve chromatogram were reduced by 25%,
65%, 85%, 30%, and 80%, respectively; 4 and 3 in-
creased by 5% and 25%; and 2 and I remain un-
changed. Table 2 gives the results of analysis of the
various subpeaks of peak 7. These data indicate that
thymol did not have any effect on the various sub-
peaks of peak 7. On the contrary, hydrochloric acid
reduced all subpeak concentrations (except 7g) by
35 to 90%. Consequently, all urine collections for
middle molecule analyses were made with 10%
thymol in isopropanol as the preservative.
Analysis of the serum of several nondialyzed ure-
mic patients indicated much higher levels of some
peak 7 subpeaks than had previously been observed
in the same patients. A closer examination showed
Table 2. Effect of method of urine preservation on peak 7
subpeaks in urine from normal subjects'
Peak
Concentration, PH U/rn!
Urine
Urine +
10% thymol
in isopropanol
Urine +
concentrated
hydrochloric acid
7a0
7a
7b
7c
7c2
7d
7e
7f
7g
50
140
385
370
ND
117
ND
495
235
50
141
354
383
ND
98
ND
474
250
16
25
42
83
ND
69
ND
280
230
a PHU is peak-height units. ND denotes nondetectable. vania
that in each case the patient had received a drug
shortly before collection of the serum sample.
Amounts of each of these drugs (aminophylline, fur-
osemide, methyldopa) were added to samples of
normal serum to give a final concentration similar to
that expected in the patient's serum based on the
prescribed dose. Analysis of these samples showed
that each drug produced one or more peaks in the
peak 7 ion-exchange chromatograms. These results
are summarized in Table 3. It is probable that these
comparatively small molecular weight drugs (200 to
300 daltons) and acetate eluted in the middle mole-
cule range because of interactions between charged
groups on the molecules and residual ion exchange
sites on the molecular sieve gel. Also, solutions of
the drugs in isotonic saline did not always produce
peaks in the ion-exchange chromatogram. In addi-
tion, it is possible that the artifactual peaks were not
due to pure drug but its metabolites, or pre-
servatives present in the particular formulation
used. As a result of these findings, we have endeav-
ored to limit our studies to patients who are not on
drug therapy, apart from oral phosphate and potas-
sium binders, sodium carbonate, and vitamin sup-
plements. If a patient is receiving other drugs, their
potential as artifacts should be investigated.
Comparison of different body fluids. As indicated
in Figs. 2 and 4 and in Table 4, there were sub-
stantial differences between the chromatograms of
normal and uremic sera, with all peak heights being
elevated in the latter. Analysis of red cell hemo-
lysates produced rather unexpected results, as
shown in Table 4: not only were the levels of sub-
peaks 7c1 to 7e substantially higher (6 to 15 times)
than they were in the corresponding serum samples,
but the levels in normal and uremic samples were
similar. The concentrations of subpeak 7g were also
Table 3. Drugs producing artifactual peaks in ion-exchange
chromatogram of peak 7
Position of
Drug
Prescribed
dose
Concentration
test sample
artifactual
peaks
Aminophyllinea 100mg
3 per day
1.25 mg/mI 7c1,7d
Furosemide5 250-1000 mg
daily
0.08 mg/mI 7c2, 7d, 7f
Methyldopa' 500mg
4 per day
0.5 mg/mI 7c1,7c2
a Cardophyllin®, Hamilton Laboratories, Adelaide, Australiab Lasix®, Hoechst Australia, Melbourne, Australia
Aldomet®, Merck, Sharp and Dohme, West Point, Pennsyl-
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Table 4. Comparison of levels of peak 7 subpeaks in serum and
red cell hemolysate samples from normal subjects and
patients with uremiaa
Concentration, PHU/mi
Peak
Serum Red cell hemolysate
Normal Uremic Normal Uremic
7a0 ND 4±4 ND ND
7a ND 16±7 ND ND
7b 1±2 23± 9 ND ND
7c1 3 2 36 2 318 137 559 477
7c2 5 2 34 9 195 28 217 54
7d ND 22 9 256 88 167 96
7e 2 I 40(n = 2) 426 31 328 157
7f 10±4 59±24 ND ND
7g 25 4 116 50 46 14 67 14
7h ND ND 50 6 131 39
a Values are the means SD of paired sera and red cell hemo-
lysate samples from three normal and three uremic subjects.
PHU is peak-height units. ND denotes nondetectable.
similar in normal and uremic red cell hemolysates,
but the levels were comparable to those in the sera.
Subpeaks 7a, 7b, and 7f did not appear in either nor-
mal or uremic red cell hemolysates, but an addition-
al subpeak, 7h, with an elution volume of 8.9 ml was
observed.
The chromatograms for both normal and uremic
urine showed a similar pattern to those observed for
sera (Figs. 2 and 4).
Discussion
Fürst et al described a two-stage chromatograph-
ic procedure for the analysis of middle molecules in
normal and uremic body fluids [2, 3]. By modifying
their procedure, we have established a method that
enables analyses to be completed in substantially
shorter times, 3.25 hours compared with 8 hours,
without loss of resolution. In fact, resolution is im-
proved in the region of subpeaks 7c1 and 7c2, which
are routinely separated in our system in contrast to
the occasional separation reported elsewhere [3].
Subpeaks 7a to 7e have also been reported not to
occur in normal plasma [3], whereas due to im-
proved sensitivity we routinely observe subpeaks
7b, 7c1, 7c2, and 7e, albeit in very low concentra-
tions (Table 4).
The reduction in analysis time from 8.0 to 3.25
hours is due to an increase in buffer flow rates, from
4.8 to 10.0 mllhr in the molecular-sieve column, and
from 6.0 to 12.5 ml/hr in the ion-exchange column.
These flow rates appear optimal for our system, as
decreasing the flow does not result in any improve-
ment in resolution, whereas it falls off rapidly at
higher flow rates.
When peaks 8 and 9 were eluted through the ion-
exchange column, no subpeaks were observed. It
appears that these higher molecular-weight species
are absorbed to the top of the ion-exchange column
and not eluted by the gradient. In particular, this
was the case with a red cell hemolysate in which a
small amount of hemoglobin had leaked through the
ultrafiltration membrane during sample deprotein-
ization. When peak 9 from this sample was eluted
through the ion-exchange column, a narrow red
band of hemoglobin was visible at the top of the gel
on completion of the gradient.
To achieve maximum resolution, care must be
taken in both deproteinizing the sample and pre-
paring the molecular sieve and ion-exchange gels. If
the maximum centrifugal force of x l000g recom-
mended for Centriflo® cones is exceeded, protein
leakage occurs resulting in a large peak (peak 9) at
the void volume of the molecular sieve column.
This can obscure later peaks. The molecular sieve
gel should be swollen in several changes of 0.01 M
Tns buffer (pH, 8.6) over a 5-hour period while
being heated over a boiling water bath. The ion-ex-
change gel should be swollen in several changes of 1
M sodium chloride in 0.01 M Tris buffer (PH, 8.6)
over a period of 24 hours followed by several
changes of 0.01 M Tris buffer over another 24 hours.
This procedure minimizes differences in elution vol-
umes of peaks arising from different batches of ion-
exchange gel.
For a two-stage chromatographic separation and
by using peak heights rather than areas as a mea-
sure of concentration, the above procedure gives
excellent quantitative results over the range of con-
centrations so far encountered in the samples ana-
lyzed. Reproducibility is adequate, with coeffi-
cients of variation for peak elution volumes of  2%
and for peak heights of < 9% and mostly <7%. In
addition, an excellent linear relationship (r> 0.99)
is found between peak height and concentration for
all peaks over a 16-fold concentration range.
Establishing that molecules from different
sources are identical by chromatography requires
identical behavior of the molecules in at least two
and preferably three or more different solvent sys-
tems. As we have only shown identical behavior in
one system, there is a remote yet finite possibility
that the middle molecule peaks in urine, sera, and
red cell hemolysate samples represent absorbances
from different but closely related molecules. Posi-
tive species identification is currently being at-
tempted in our laboratories.
The nature of the moieties separated in this analy-
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sis and their role, if any, in the pathophysiology of
uremia still remain to be elucidated. Because, how-
ever, the levels of all subpeaks, except 7g, were re-
duced markedly in the presence of hydrochloric
acid, it is probable that peaks 7a to 7f contain pep-
tide material.
If any of the peak 7 components subsequently
prove to be uremic toxins, then the high levels of
subpeaks 7c1 to 7e found in red cell hemolysates in
both normal and uremic individuals are unexpected.
The large concentration differences between hemo-
lysates and corresponding sera in normal subjects
suggest that uremic middle molecules originate
within the red cell and that they are either protein
bound within the cell or are transferred between
cells and plasma by active transport. The similarity
between hemolysate levels in normal subjects and
patients with uremia further suggests that the red
cell handling of these species is not impaired by ure-
mia. In contrast, as subpeaks 7a0, 7a, 7b, and 7f
were not detected in red cell hemolysates, their ori-
gin is probably from outside the red cells and they
probably do not cross the red cell membrane. Be-
cause red blood cell survival is considerably re-
duced in patients with uremia (73 days compared
with 115 days for normal subjects [5]), the consid-
erably higher sera levels of peaks 7c through 7f in
patients with uremia could be the result of either red
cell destruction or red cell leakage coupled with
poor renal excretion.
The apparent distribution of the various com-
ponents between serum and red cells also may have
important consequences in the further study of
these species and their kinetics. First, care must be
taken when obtaining samples to avoid any hemo-
lysis before red cells are separated from serum to
prevent artifactual results. Second, any mathematical
models used to manipulate levels of these species
during prospective clinical studies of their toxicity
must take into account the possible two-com-
partmental nature of their distribution. This obser-
vation, together with a recent report [6] showing the
rate-limiting nature of intercompartmental transfer
on the dialytic removal of middle molecules, casts
doubt on the usefulness of such concepts as the
dialysis index [7] to predict dialysis times from the
calculated removal of a hypothetical middle mole-
cule species from a single body pool.
Sutnmary. Our results show that caution is neces-
sary in interpreting results of middle molecule anal-
yses. Artifacts can give high results in serum analy-
ses due to drugs or hemolysis of red blood cells and
in analyses of dialysate due to acetate. Low results
in analyses of urine will be obtained if hydrochloric
acid is used as a preservative, thus negating clear-
ance measurements. These can be overcome, how-
ever, by careful attention to collection of specimens
for analysis, deproteinization, manipulation of
chromatography conditions and taking careful note
of drug and dialysis conditions. Serum middle mole-
cule levels are elevated in patients with uremia
compared with normal subjects. Preliminary data
on middle molecule fractionations of red blood cell
hemolysates show significant differences between
plasma and red cell concentrations for both normal
and uremic subjects. Red cell levels, however, are
similar in both normal subjects and patients with
uremia. To date, none of these middle molecule
species has been specifically connected with uremic
symptomatology. In addition, although urine and
red cell chromatograms are almost identical in form
to those of plasma, there is no absolute proof that
the species are identical. It must, therefore, be con-
sidered highly premature to consider the use of any
middle molecule species as a marker for the assess-
ment of the adequacy of dialysis therapy.
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